当前位置：
X-MOL 学术
›
Eur. J. Heart Fail.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction.
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2020-03-25 , DOI: 10.1002/ejhf.1787 Frank Kramer 1 , Sebastian Voss 2 , Lothar Roessig 3 , Bernd-Wolfgang Igl 4 , Javed Butler 5 , Carolyn S P Lam 6, 7, 8 , Aldo P Maggioni 9 , Sanjiv J Shah 10 , Burkert Pieske 11, 12, 13, 14
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2020-03-25 , DOI: 10.1002/ejhf.1787 Frank Kramer 1 , Sebastian Voss 2 , Lothar Roessig 3 , Bernd-Wolfgang Igl 4 , Javed Butler 5 , Carolyn S P Lam 6, 7, 8 , Aldo P Maggioni 9 , Sanjiv J Shah 10 , Burkert Pieske 11, 12, 13, 14
Affiliation
The effects of vericiguat vs. placebo on high‐sensitivity C‐reactive protein (hsCRP) and serum uric acid (SUA) were assessed in patients with heart failure with reduced ejection fraction (HFrEF) in the Phase 2 SOCRATES‐REDUCED study (NCT01951625).
中文翻译：
评价Vericoguat治疗的心力衰竭患者射血分数降低的高敏C反应蛋白和尿酸。
在SOCRATES-REDUCED 2期研究中评估了心力衰竭患者射血分数降低的心力衰竭患者中Vericiguat vs.安慰剂对高敏C反应蛋白（hsCRP）和血清尿酸（SUA）的影响（NCT01951625） 。
更新日期：2020-03-25
中文翻译：
评价Vericoguat治疗的心力衰竭患者射血分数降低的高敏C反应蛋白和尿酸。
在SOCRATES-REDUCED 2期研究中评估了心力衰竭患者射血分数降低的心力衰竭患者中Vericiguat vs.安慰剂对高敏C反应蛋白（hsCRP）和血清尿酸（SUA）的影响（NCT01951625） 。
京公网安备 11010802027423号